Corvas appoints Randall E. Woods as president and chief executive officer.SAN DIEGO--(BUSINESS WIRE)--May 13, 1996--Corvas International Inc. (NNM NNM Network Node Manager NNM NASDAQ National Market (financial) NNM National Nutrition Month (March; American Dietetic Association) NNM Naryan-Mar (Russia) NNM Net New Money :CVAS CVAS Controlled Vehicle Access System CVAS Configuration Verification Accounting System (NASA) ) Monday announced the appointment of Randall E. Woods as president, chief executive officer and director. Woods brings more than 23 years of pharmaceutical industry experience, serving most recently as president of U.S. operations for Boehringer Mannheim Pharmaceuticals Corp. (BMPC BMPC Battalion Mobile Production Center ), a division of Corange Ltd. As previously announced, David S. Kabakoff, Ph.D., president and chief executive officer, will continue as chairman of the board of directors. "Randy is a seasoned executive with experience in both biopharmaceuticals and traditional pharmaceuticals. His proven business leadership skills will serve Corvas well as we move toward product development and commercialization. I look forward to working with Randy to evolve the company's strategy," said Kabakoff. During his tenure as president of BMPC's U.S. pharmaceutical operations, Woods, 44, was responsible for developing the strategy and business plan during its start-up phase. Additionally, he spearheaded the completion of several collaborative business development projects. Before becoming president, Woods served as vice president of marketing and sales. Prior to joining BMPC in 1993, Woods held various sales and marketing management positions at Eli Lilly Eli Lilly can refer to:
"I am enthused about the opportunity to lead Corvas through the next stage of corporate development. The innovative products, outstanding scientific team, strong technology base and key strategic alliances with major pharmaceutical companies are all aspects that attracted me to this position," said Woods. "I look forward to being part of a company that is a leader in its field." Corvas International Inc. is a biopharmaceutical company engaged in the design and development of a new generation of therapeutic agents for the prevention and treatment of major cardiovascular and inflammatory diseases. Corvas is currently collaborating with Schering-Plough Corp. in the development of oral thrombin inhibitors for chronic cardiovascular diseases, with Pfizer Inc. to develop neutrophil neutrophil /neu·tro·phil/ (noo´tro-fil) 1. a granular leukocyte having a nucleus with three to five lobes connected by threads of chromatin, and cytoplasm containing very fine granules; cf. heterophil. 2. inhibitory factor (NIF NIF See: Note issuance facility ) as a possible stroke therapy, and has product licensing agreements with Ortho Diagnostic Systems Inc. (a Johnson & Johnson company) and Centocor Inc. For background information on Corvas' technology and product development programs, please contact Angela Hartley, director, Investor Relations Investor relations The process by which the corporation communicates with its investors. , at Corvas at 619/455-9800. For information on Corvas International Inc. via facsimile at no cost, call 800/PRO-INFO and enter ticker symbol Ticker Symbol An arrangement of characters (usually letters) representing a particular security listed on an exchange or otherwise traded publicly. When a company issues securities to the public marketplace, it selects an available ticker symbol for its securities which investors CVAS. CONTACT: Corvas International Inc., San Diego John E. Crawford, Angela L. Hartley, 619/455-9800 angela_hartley@corvas.com |
|
||||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion